Your session is about to expire
← Back to Search
Patient-Reported Outcomes After Breast Biopsy
N/A
Waitlist Available
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients treated at DUMC, DFCI, MDACC, MGH, NWH, or DFCI @ SSH with a diagnosis of DCIS, LCIS, ADH, or ALH
Age 18 or more at index diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Awards & highlights
Study Summary
This trial is looking at how people feel after a breast biopsy for certain conditions. It will help doctors understand how patients cope emotionally and physically.
Who is the study for?
This trial is for adults who've had a breast biopsy showing atypical lesions and have been treated at certain study sites. They must be able to read English or Spanish, provide consent, and have at least one year of follow-up data post-diagnosis. Those with other cancers within the last five years or invasive breast cancer ever are excluded.Check my eligibility
What is being tested?
The PORTAL study is not testing a drug but rather collecting information through surveys on how patients feel physically and emotionally after treatment for specific non-invasive breast conditions like ADH, ALH, LCIS, or DCIS.See study design
What are the potential side effects?
Since this trial involves completing surveys about patient experiences post-treatment rather than testing medications or therapies, there are no direct side effects associated with the interventions being studied.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was treated for early breast changes at a specified hospital.
Select...
I was 18 or older when my condition was first diagnosed.
Select...
I have had breast conditions in both breasts, either at the same time or at different times.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient reported outcome was scheduled from at least one year from diagnosis. participants' time from diagnosis to completing a survey was an average of 45.8 months in this study cohort.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The Measures Severity of Chronic Pain.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Patient-reported Outcomes SurveyExperimental Treatment1 Intervention
The survey will administered online, over the phone, or via mail.
Find a Location
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,080 Previous Clinical Trials
340,321 Total Patients Enrolled
141 Trials studying Breast Cancer
21,705 Patients Enrolled for Breast Cancer
Ann H. Partridge, MD, MPHStudy DirectorDana-Farber Cancer Institute
1 Previous Clinical Trials
257 Total Patients Enrolled
1 Trials studying Breast Cancer
257 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with invasive or microinvasive breast cancer before.I have not been diagnosed with any cancer other than non-melanoma skin cancer in the last 5 years.I was treated for early breast changes at a specified hospital.I was 18 or older when my condition was first diagnosed.I was diagnosed with a specific breast condition between 2012 and 2017.I have had breast conditions in both breasts, either at the same time or at different times.I have had DCIS before my current cancer or it came back after treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Patient-reported Outcomes Survey
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any opportunities for enrolment in this testing process?
"According to the information posted on clinicaltrials.gov, this specific medical study is not actively recruiting at this time; it was initially made available on December 1st 2017 and last updated November 22nd 2022. However, there are over two-thousand other trials that currently require volunteers."
Answered by AI
What is the geographical scope of this trial?
"The current recruitment process for this medical trial involves 6 different sites, located in Houston, Durham and Newton. These are supplemented by an additional 6 facilities to aid patients with proximity to the closest clinic. For reduced travel demands when enrolling, it is recommended that participants opt for a local site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger